Accord Healthcare Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Accord Healthcare Ltd.
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
Intas and mAbxience have announced an exclusive licensing agreement covering mAbxience’s etanercept biosimilar candidate in more than 150 countries worldwide, including Europe and the US.
In a blow to several generics firms – albeit one telegraphed by a decision handed down nine months ago – the European Commission has ordered the removal of marketing authorizations for generic versions of Biogen’s MS brand, Tecfidera.
Now that the first license for a drug has been obtained in partnership with the program, work will begin to ensure other companies that make the product adopt the new licensed indication.
- Generic Drugs
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.